These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
859 related articles for article (PubMed ID: 18724529)
1. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation]. Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529 [TBL] [Abstract][Full Text] [Related]
2. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845 [TBL] [Abstract][Full Text] [Related]
3. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression. Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Callera F; Cavenaghi L; de Melo CM Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728 [TBL] [Abstract][Full Text] [Related]
5. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558 [TBL] [Abstract][Full Text] [Related]
6. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285 [TBL] [Abstract][Full Text] [Related]
9. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046 [TBL] [Abstract][Full Text] [Related]
10. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related]
11. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278 [TBL] [Abstract][Full Text] [Related]
12. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. McQuaker I; Haynes A; Stainer C; Byrne J; Russell N Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673 [TBL] [Abstract][Full Text] [Related]
13. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
14. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets. Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276 [TBL] [Abstract][Full Text] [Related]
15. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [TBL] [Abstract][Full Text] [Related]
16. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Remacha AF; Martino R; Sureda A; Sarda MP; Solá C; Tugues D; Amill B; Garcia J; Oliver A Bone Marrow Transplant; 1996 Feb; 17(2):163-8. PubMed ID: 8640161 [TBL] [Abstract][Full Text] [Related]
17. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594 [TBL] [Abstract][Full Text] [Related]
18. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. de Bont ES; Guikema JE; Scherpen F; Meeuwsen T; Kamps WA; Vellenga E; Bos NA Cancer Res; 2001 Oct; 61(20):7654-9. PubMed ID: 11606408 [TBL] [Abstract][Full Text] [Related]
19. [Analysis of phenotypes and kinetics of CD34+ cells and lymphocytes in donors of hematopoietic stem cells for allogenic transplantation]. Klabusay M; Suková V; Korístek Z; Mayer J; Vorlícek J Cas Lek Cesk; 2003; 142(7):410-6. PubMed ID: 14515444 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]